Paris, March 4, 2010 – Cellectis (Alternext: ALCLS), the French genome
engineering specialist, has announced that BASF Plant Science has just
broadened its license to use Cellectis’ meganuclease technology. BASF Plant
Science is the plant biotechnology business of one of the world’s leading chemical
company, BASF, and specializes in the research, development and
commercialization of transgenic crops.
This agreement extends the license signed by Cellectis and BASF Plant Sciences
in January 2006. Under a non-exclusive license, BASF Plant Science will use
meganucleases engineered by Cellectis to make targeted modifications of plant
genomes.
Financial terms and conditions of the agreement were not disclosed.
“The broadening of an agreement with a high-profile company that has been using
our tools and technology for three years is very good news,” said André Choulika,
Cellectis CEO. “It confirms that major players in the global agricultural
biotechnology field have a high level of confidence that Cellectis’ meganuclease
technology has an unparalleled ability to develop the next generation of high
added value crops.”
To find out more about BASF Plant Science, please see the web site at:
http://www.basf.com/biotechnology.
About Cellectis
Cellectis is a pioneer in the field of genome engineering. The company designs and markets
innovative tools -meganucleases. These molecular scissors enable targeted modifications to DNA,
with applications in the research, biomanufacturing, agrobiotechnology and therapeutic sectors.
To date, Cellectis has formed over 20 academic research partnerships and has established more
than 50 agreements with pharmaceutical laboratories, seed producers and biotech companies
across the world. The company holds exclusive rights to a portfolio of over 260 patents granted or
pending.
Since 2007, Cellectis has been listed on the NYSE-Euronext Alternext market (code: ALCLS) in
Paris and has secured over €70 million in funding since inception.
More information at www.cellectis.com
Disclaimer
This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an
offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that
relate to the Company’s objectives. Such forward-looking statements are based on the current expectations and
assumptions of the Company’s management only and involve risk and uncertainties. Potential risks and uncertainties
include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be
continued growth in the relevant market and demand for the Company’s products, new products or technological
developments introduced by competitors, and risks associated with managing growth. Unfavorable developments in
connection with these and other risks and uncertainties described, in particular, in the Company’s prospectus prepared in
connection with its IPO and on which the French Autorité des marchés financiers (“AMF”) granted its visa no. 07-023 on
January 22, 2007, could cause the Company to fail to achieve the objectives expressed by the forward-looking statements
above.
